U.S. FDA To Review Mylan's Application For Generic Copaxone; India Partner Natco Expects To Cross More Hurdles
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Oncology drug maker Natco and its partner Mylan moved a step closer to a possible launch of a generic version of Teva's blockbuster multiple sclerosis drug Copaxone (glatiramer) after U.S. FDA accepted Natco's application for review